Buy Melanotan 2 in Australia — Body Pharm MT-II: Mechanism, Receptors & Research Overview
Melanotan 2 (MT-II) is a synthetic cyclic heptapeptide (Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, ~1024.2 g/mol) that acts as a non-selective agonist at four of the five melanocortin receptors — MC1R, MC3R, MC4R and MC5R — with markedly weaker activity at MC2R. That promiscuous binding profile is why a single molecule can drive pigmentation (MC1R), modulate energy partitioning (MC3R), suppress appetite and trigger erectile response (MC4R) at the same dose. JCSG.org stocks Body Pharm MT-II for Australian researchers — order now via the buy box above.
Why receptor-level detail matters
Australian regulators treat MT-II as an unapproved, prescription-only peptide. The TGA's 24 January 2025 advisory reiterated risks including melanoma and atypical naevi linked to illicit cosmetic use. The sections below map each receptor interaction to its downstream pathway, drawing on peer-reviewed pharmacology and a 2024 dermatology review of chronic MC1R activation. That level of mechanistic detail matters for researchers designing assays that need to isolate specific receptor effects rather than conflate multiple parallel pathways.
Key takeaways
- Melanotan 2 is a cyclic heptapeptide that binds four melanocortin receptors (MC1R, MC3R, MC4R, MC5R) non-selectively, driving pigmentation, appetite suppression and erectile effects from a single dose.
- The TGA classifies MT-II as unapproved and prescription-only; the 24 January 2025 advisory warns of melanoma, atypical naevi and systemic adverse effects.
- MC1R activation triggers eumelanin synthesis via cAMP–PKA–MITF–tyrosinase signalling; MC4R drives appetite suppression and pro-erectile signalling in the hypothalamus and brainstem.
- MC3R modulates energy partitioning rather than appetite; human data isolating this effect remain absent.
- No modern (2020–2026) radioligand study has refreshed binding-affinity comparisons for MT-II; pre-2020 Ki values should be treated as historical reference material.
- Adverse effects documented in observational data (melanoma, priapism, cerebral oedema) derive from spontaneous reports without causality adjudication.
- Ready to order? Get Body Pharm Melanotan 2 on JCSG.org — see the current price in the buy box above.
What is melanotan 2? A research definition
Melanotan 2 is a synthetic cyclic heptapeptide analogue of α-melanocyte-stimulating hormone (α-MSH), with the sequence Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, molecular formula C50H69N15O9, and a molecular weight of approximately 1024.2 g/mol. It is not approved for any therapeutic or cosmetic indication in Australia and is the subject of an active TGA safety advisory dated 24 January 2025.
Structural distinction from α-MSH
Endogenous α-MSH is a linear 13-residue peptide. Melanotan 2 truncates the sequence and locks it into a ring via a lactam bridge between the β-carboxyl of Asp and the ε-amino group of Lys. That constraint stabilises the His-D-Phe-Arg-Trp pharmacophore (the conserved melanocortin "message" motif) in an active-state conformation, which confers higher receptor affinity and markedly greater metabolic stability than the linear hormone. The cyclisation alters conformational dynamics and receptor residence time; it does not introduce a new pharmacophore. This is why MT-II retains agonist activity across MC1R, MC3R, MC4R and MC5R.
Naming conventions
In peer-reviewed literature the compound appears as melanotan II, melanotan-2, MT-II, or MT-2interchangeably. The Roman-numeral form is most common in pharmacology journals, while "melanotan 2" dominates search results and consumer-facing copy. None of these abbreviations should be confused with afamelanotide (Scenesse), a structurally distinct linear α-MSH analogue that is ARTG-registered for erythropoietic protoporphyria.
Melanotan II vs Melanotan I: key structural differences
Melanotan I and melanotan II are pharmacologically and legally distinct compounds despite sharing the α-MSH-derived His-Phe-Arg-Trp pharmacophore. Melanotan I (afamelanotide) is a linear 13-amino-acid analogue of α-MSH delivered as a 16 mg controlled-release subcutaneous implant under the trade name Scenesse. Melanotan 2 is a cyclic heptapeptide closed by a lactam bridge between the Asp side-chain carboxyl and the Lys ε-amine.
Why the ring matters
The lactam constraint in MT-II reduces conformational entropy, locking the message motif into a receptor-active geometry. This raises affinity at MC1R, MC3R, MC4R and MC5R and slows proteolytic clearance relative to linear α-MSH and afamelanotide. Secondary sources describe MT-II as a "non-selective melanocortin receptor agonist" with broadly comparable low-nanomolar affinity across MC1R/3R/4R/5R. No modern (2020–2026) primary radioligand study has produced a head-to-head Ki comparison between MT-I and MT-II.
Regulatory asymmetry
Afamelanotide is registered on the ARTG for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria. Melanotan 2 has no equivalent approval in Australia, the EU, or the US, and is the subject of an active TGA consumer warning dated 24 January 2025.
Melanocortin receptor subtypes: MC1R, MC3R, MC4R
The melanocortin system comprises five class A GPCRs (MC1R–MC5R) activated by post-translational POMC products: α-MSH, β-MSH, γ-MSH, and ACTH. Melanotan 2 is a non-selective agonist at four of the five subtypes (MC1R, MC3R, MC4R, MC5R), with weak activity at MC2R because the ACTH-binding pocket requires the N-terminal extension absent from MT-II's heptapeptide core.
Expression and affinity matrix
| Receptor | Primary expression | Endogenous ligand | MT-II Ki (nM) |
|---|---|---|---|
| MC1R | Melanocytes, keratinocytes, immune cells | α-MSH | ~0.1–1 nM (pre-2020, stale) |
| MC2R | Adrenal cortex (zona fasciculata) | ACTH (selective) | Negligible — MT-II lacks ACTH N-terminus |
| MC3R | Hypothalamus (ARC, VMH), placenta, gut | γ-MSH (preferred), α-MSH | ~1–5 nM (pre-2020, stale) |
| MC4R | CNS — PVH, brainstem, spinal cord | α-MSH, β-MSH | ~0.5–2 nM (pre-2020, stale) |
| MC5R | Exocrine glands, skeletal muscle | α-MSH | ~1–5 nM (pre-2020, stale) |
The numeric ranges above derive from radioligand displacement assays on cloned human receptors published before 2020. No 2020–2026 primary study has produced a head-to-head Ki comparison for MT-II.
Downstream consequences of non-selective binding
MT-II hits MC1R (pigmentation), MC3R (energy partitioning), MC4R (appetite, autonomic tone, erectile reflex arcs) and MC5R (exocrine secretion) at overlapping low-nanomolar affinity. A single subcutaneous dose in animal or in vitro models therefore produces an entangled phenotype rather than a clean pigmentary readout.
MC1R activation: the pigmentation pathway
Melanotan 2 produces a tan by binding MC1R on epidermal melanocytes and triggering a Gs-coupled cAMP cascade that ends in eumelanin synthesis. This bypasses the UV-induced DNA damage signal that normally initiates the same pathway. The compound is described as a "sunless tanning" agent because the downstream pigmentary machinery engages directly at the receptor.
The cAMP → PKA → MITF → tyrosinase cascade
- MT-II binds the orthosteric pocket of MC1R, stabilising the active-state conformation that couples Gαs.
- Gαs activates adenylyl cyclase, raising intracellular cAMP.
- cAMP releases the catalytic subunits of protein kinase A (PKA).
- PKA phosphorylates CREB, which transactivates MITF, the master regulator of the melanocyte lineage.
- MITF upregulates tyrosinase, TRP-1 and TRP-2, shifting flux toward eumelanin (brown/black) rather than phaeomelanin.
The eumelanin bias matters mechanistically. Phaeomelanin is pro-oxidant and offers little photoprotection, whereas eumelanin absorbs across the UV spectrum. MC1R loss-of-function variants common in fair-skinned Australian populations default melanocytes to phaeomelanin output; pharmacological MC1R agonism with a non-selective ligand such as MT-II overrides that genetic set-point in cell and animal models.
Human pigmentation data and its age
The clinical anchor for MT-II tanning in humans remains Dorr et al. (1996, Journal of Urology), a small pilot in which five subcutaneous doses on alternate days produced visible darkening. No modern controlled trial has replicated that work. A 2024 review confirms MT-II has no therapeutic approval and that post-1990s human evidence consists of case reports and observational descriptions of illicit cosmetic use.
MC4R activation: CNS and behavioural effects
MC4R activation by melanotan 2 produces the centrally mediated effects most frequently reported in the MT-II literature: appetite suppression, pro-erectile signalling, and the autonomic and affective changes that accompany hypothalamic melanocortin tone. MC4R is densely expressed in the paraventricular nucleus of the hypothalamus and in brainstem nuclei controlling sympathetic outflow.
The anorexigenic arm is the mechanistic basis for the weight-loss interest the compound attracts in non-clinical settings. In rodent pharmacology, central melanocortin agonism chronically reduces body mass through combined hypophagia and increased energy expenditure, an effect attenuated in MC4R-deficient models. None of this constitutes a therapeutic claim for MT-II in humans.
Pro-erectile signalling and priapism
MC4R activation in spinal and supraspinal autonomic circuits drives penile erection independently of androgen or nitric oxide pathways. This is why non-selective melanocortin agonists produce spontaneous erections at doses well below those needed for pigmentary endpoints. Prolonged or painful erection (priapism) is the clinical expression of the same pathway and features in the user-experience data summarised by Ho et al. (2024).
Adverse CNS reports and mechanistic limits
The TGA's 24 January 2025 consumer warning referenced serious adverse reports including brain swelling associated with melanotan products. That signal is pharmacovigilance, not a resolved mechanism, and should not be conflated with the receptor-level pharmacology above.
MC3R activation: metabolic and peripheral signalling
MC3R is the least-characterised of melanotan 2's high-affinity targets. Its activation by MT-II appears to influence energy partitioning rather than appetite. Where MC4R signalling suppresses food intake and raises sympathetic output, MC3R modulates how ingested calories distribute between lean and adipose compartments. Most consumer-facing MT-II content collapses both receptors into a single "metabolic effect", which the receptor pharmacology does not support.
Expression mapping places MC3R in the arcuate and ventromedial hypothalamus, limbic structures including the ventral tegmental area, and peripheral tissues such as gut enteroendocrine cells and macrophages. Mc3r−/− mice show increased adiposity and altered feed efficiency without the marked hyperphagia seen in Mc4r−/− animals.
What the human data does and does not show
Human MT-II studies have not isolated MC3R-specific endpoints. Controlled trials remain limited to 1990s exploratory work. The observational data summarised by Ho et al. (2024) describes appetite loss and nausea without resolving which receptor subtype dominates.
Reported side effects: what the research documents
| Side effect | Proposed receptor / mechanism |
|---|---|
| New or darkening moles, increased freckling, hyperpigmentation | MC1R agonism in epidermal melanocytes; α-MSH-like cAMP signalling driving eumelanin synthesis |
| Melanoma and dysplastic naevi temporally associated with MT-II use | Sustained MC1R activation; mechanism not causally established |
| Nausea, vomiting, flushing, appetite loss | MC4R (and possibly MC3R) signalling in hypothalamic and brainstem circuits |
| Spontaneous or prolonged erections, priapism | MC4R activity in spinal and supraspinal pro-erectile pathways |
| Kidney dysfunction | Undetermined; reported in pharmacovigilance data without receptor attribution |
| Cerebral oedema (brain swelling) | Undetermined; observed in adverse-event reports |
These signals derive from observational sources, not controlled trials. The TGA's 24 January 2025 advisory draws on Database of Adverse Event Notifications (DAEN) submissions — spontaneous reports without denominator data or causality adjudication.
Regulatory status in Australia (2025–2026)
Melanotan II is not approved by the Therapeutic Goods Administration (TGA) for any indication in Australia. The agency's 24 January 2025 safety advisory states that products containing it cannot be lawfully supplied for cosmetic tanning. The advisory specifically warns that injectable melanotan products are unapproved, frequently intercepted at the border, and associated with melanoma, atypical naevi and systemic adverse events.
The compound is not named as a discrete entry in the current Poisons Standard (SUSMP), but it is regulated as a therapeutic good and treated as prescription-only in practice. Import and supply are controlled through therapeutic-goods and border legislation rather than a specific schedule listing.
Melanotan II should not be conflated with afamelanotide (Scenesse), a structurally distinct linear α-MSH analogue registered on the ARTG as a 16 mg controlled-release subcutaneous implant for the prevention of phototoxicity in adults with erythropoietic protoporphyria. Scenesse is delivered in specialist hospital settings under a controlled access programme.
Research use only
For research purposes only. Not for human consumption.
Melanotan II in structural genomics research
Melanotan II is used in structural biology as a conformationally constrained tool compound for probing the active-state geometry of melanocortin GPCRs. Its Asp-Lys lactam bridge locks the His-Phe-Arg-Trp pharmacophore into a bioactive turn, reducing entropic penalties on binding and yielding the kind of stable receptor-ligand complex that crystallography and single-particle cryo-EM workflows demand.
No deposited structure to date captures MT-II itself bound to MC1R, MC3R, MC4R, or MC5R. The closest reference points are the cryo-EM structure of the human MC4R–Gs complex with setmelanotide and post-2020 MC1R–agonist structures resolved with α-MSH-derived peptides. Mapping MT-II's pharmacophore onto these scaffolds is a modelling exercise rather than a direct observation.
The medicinal-chemistry rationale for the cyclic lactam was to improve proteolytic stability and extend receptor residence time relative to linear α-MSH — not to introduce a novel pharmacophore. Because the cycle constrains conformation rather than chemistry, MT-II remains non-selective across MC1R, MC3R, MC4R, and MC5R.
Order Body Pharm Melanotan 2 on JCSG.org — Australia
JCSG.org is your go-to Australian source for Body Pharm research peptides, including Melanotan 2. We carry characterised MT-II reference material dispatched promptly to Australian researchers. See the current price in the buy box above and add Body Pharm Melanotan 2 to your cart now. Need to compare the full range? Browse and buy all Body Pharm peptides available in Australia on JCSG.org.
Related peptides — browse the full Australian catalogue
Working in adjacent melanocortin, tanning, or appetite-regulation research? Explore the complete Body Pharm peptide catalogue for Australia on JCSG.org to find the right tool compound for your assay. Order Melanotan 2 today — stock is limited, so secure yours via the buy box above before it sells out.
Last reviewed: May 2026.